Baris Ata Borsa
Co-founder and CTO, Theralia AB
I am a medical microbiologist with a large experience on fighting with infections caused by MDR bacteria in different hospitals with high AMR rates. Since 2018, I have been working on developing an innovative therapeutic approach, therapeutic oligonucleotides activated by nucleases or TOUCANs, that enables pathogen-specific delivery of potent antibacterial molecules to the infection site with high efficacy and low toxicity.